Your session is about to expire
← Back to Search
Radiation + Chemotherapy for Advanced Lung Cancer
Study Summary
This trial will test if a new cancer treatment is effective in treating locally-advanced NSCLC. The treatment involves radiation and chemotherapy, with or without additional consolidation chemotherapy. A total of 60 people will be enrolled over 4 years.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lung function is within the required range, and if I'm using oxygen, it's stable.I am 18 years old or older.I can take care of myself but might not be able to do heavy physical work.My blood counts and kidney and liver functions are within normal ranges.I have been cancer-free for at least 3 years, except for certain low-risk or in situ cancers.My lung tumor is close to the center and near important airways.My CT scan shows a non-cancerous fluid buildup in my chest that's too small for a fluid removal procedure.My doctor thinks I am a good candidate for durvalumab treatment.I've had chest radiation before that might affect new treatment.Women who can have children must have a negative pregnancy test before joining the study.I have received treatment that affects my whole body for lung cancer.My cancer is at stage II or III, and my primary tumor is 7 cm or smaller.My lung cancer diagnosis was confirmed through lab tests.
- Group 1: Single Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research endeavor currently taking on new participants?
"The clinicaltrials.gov entry for this study reveals that it is no longer recruiting participants; the listing was first made available on May 11th 2017 and last edited November 16th 2022. Despite this, there are presently 1,688 other trials actively enrolling patients."
To what extent is stereotactic body radiation therapy hazardous for individuals?
"Due to the lack of efficacy data, SBRT's safety was rated as a 2 on our scale. This is justified by the fact that it is only in Phase 2 clinical trials at this moment."
How many individuals are participating in this medical experiment?
"This clinical trial is no longer actively enrolling patients. Initially posted on May 11th, 2017 and most recently updated on November 16th 2022, this study has reached its recruitment limit. However, 3 ongoing trials pertaining to lung health are still recruiting as well as 1,685 SBRT studies that need participants."
What other tests have been performed to evaluate the effectiveness of SBRT?
"Currently, there are 1685 trials involving stereotactic body radiation therapy (SBRT), with 431 of them in the late stages. Shanghai is one of the many cities running these studies and globally, SBRT clinical trials are taking place at 89647 sites."
What maladies do medical professionals typically utilize SBRT for?
"SBRT is a potential treatment option for metastatic ureter urothelial carcinoma, lymphomas of the non-Hodgkin variety, and Merkel cell cancer."
Share this study with friends
Copy Link
Messenger